BR112012012151B8 - lipossoma de irinotecano ou cloridrato de irinotecano, método de preparação do mesmo, bem como injeção de lipossoma e processo de preparação da mesma - Google Patents

lipossoma de irinotecano ou cloridrato de irinotecano, método de preparação do mesmo, bem como injeção de lipossoma e processo de preparação da mesma

Info

Publication number
BR112012012151B8
BR112012012151B8 BR112012012151A BR112012012151A BR112012012151B8 BR 112012012151 B8 BR112012012151 B8 BR 112012012151B8 BR 112012012151 A BR112012012151 A BR 112012012151A BR 112012012151 A BR112012012151 A BR 112012012151A BR 112012012151 B8 BR112012012151 B8 BR 112012012151B8
Authority
BR
Brazil
Prior art keywords
liposome
preparation
irinotecan
hydrochloride
well
Prior art date
Application number
BR112012012151A
Other languages
English (en)
Other versions
BR112012012151B1 (pt
BR112012012151A2 (pt
Inventor
Yu Chengxia
Lei Guofeng
Chen Liang
Tong Xinyong
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of BR112012012151A2 publication Critical patent/BR112012012151A2/pt
Publication of BR112012012151B1 publication Critical patent/BR112012012151B1/pt
Publication of BR112012012151B8 publication Critical patent/BR112012012151B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

lipossoma e irinotecano ou seu cloridrato e seu método de preparação. a presente invenção refere-se a um lipossoma de irinotecano ou seu cloridrato e seu método de preparação. o lipossoma compreende irinotecano ou seu cloridrato, foslolipídio neutro e colesterol, em que a razão em peso de colesterol para fosfolipídio neutro é de 1:3-5. o dito lipossoma é preparado pelo método de gradiente iônico.
BR112012012151A 2009-12-03 2009-12-03 lipossoma de irinotecano ou cloridrato de irinotecano, método de preparação do mesmo, bem como injeção de lipossoma e processo de preparação da mesma BR112012012151B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2009/075298 WO2011066684A1 (zh) 2009-12-03 2009-12-03 伊立替康或盐酸伊立替康脂质体及其制备方法

Publications (3)

Publication Number Publication Date
BR112012012151A2 BR112012012151A2 (pt) 2016-04-12
BR112012012151B1 BR112012012151B1 (pt) 2021-01-19
BR112012012151B8 true BR112012012151B8 (pt) 2021-05-25

Family

ID=44114598

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012151A BR112012012151B8 (pt) 2009-12-03 2009-12-03 lipossoma de irinotecano ou cloridrato de irinotecano, método de preparação do mesmo, bem como injeção de lipossoma e processo de preparação da mesma

Country Status (22)

Country Link
US (2) US20120282325A1 (pt)
EP (1) EP2508170B1 (pt)
JP (1) JP5645954B2 (pt)
KR (2) KR20120089754A (pt)
CN (1) CN102271659B (pt)
AU (1) AU2009356132B2 (pt)
BR (1) BR112012012151B8 (pt)
CA (1) CA2782911C (pt)
CY (1) CY1116811T1 (pt)
DK (1) DK2508170T3 (pt)
ES (1) ES2547698T3 (pt)
HK (1) HK1159482A1 (pt)
HR (1) HRP20150911T1 (pt)
HU (1) HUE027467T2 (pt)
MX (1) MX2012005775A (pt)
PL (1) PL2508170T3 (pt)
PT (1) PT2508170E (pt)
RU (1) RU2526114C2 (pt)
SI (1) SI2508170T1 (pt)
SM (1) SMT201500245B (pt)
WO (1) WO2011066684A1 (pt)
ZA (1) ZA201203316B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935066B (zh) * 2011-08-16 2014-09-17 齐鲁制药有限公司 一种伊立替康脂质体制剂及其制备方法
EP2768484B1 (en) 2011-10-21 2019-07-24 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
RU2014144945A (ru) * 2012-04-10 2016-05-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Бис-полимерные липид-пептидные конъюгаты и наночастицы из них
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN102697720B (zh) * 2012-06-29 2014-01-15 海南灵康制药有限公司 盐酸伊立替康脂质纳米粒注射剂
CN103181898B (zh) * 2012-11-23 2016-03-09 杭州师范大学 一种奥沙利铂脂质体及其应用
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
SI3138555T1 (sl) 2014-04-30 2021-06-30 Fujifilm Corporation Liposomski sestavek in proizvodni postopek zanj
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
ES2848118T3 (es) 2015-08-20 2021-08-05 Ipsen Biopharm Ltd Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
TWI778942B (zh) 2015-08-21 2022-10-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康（ｉｒｉｎｏｔｅｃａｎ）及奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）之組合療法治療轉移性胰臟癌的方法
RU2732567C2 (ru) 2015-10-16 2020-09-21 Ипсен Биофарм Лтд. Стабилизированные фармацевтические композиции камптотецина
CN107281102A (zh) * 2016-04-11 2017-10-24 江苏竞诺择生物医药科技有限公司 一种用于结直肠肿瘤治疗的药物微粒组合物
CN107456456A (zh) * 2016-06-03 2017-12-12 江苏恒瑞医药股份有限公司 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
CN109475497A (zh) * 2016-06-28 2019-03-15 奇默里克斯公司 布林西多福韦的制剂
CN106109415B (zh) * 2016-07-26 2019-01-29 金华市人民医院 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用
WO2018048752A1 (en) 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions
SG11201903326RA (en) * 2016-10-28 2019-05-30 Servier Lab Liposomal formulation for use in the treatment of cancer
BR112019007844A2 (pt) * 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
US10722465B1 (en) * 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
CN109675047B (zh) * 2019-01-07 2020-12-04 中国科学院化学研究所 一种对具有游离羟基的化合物进行脂质体修饰的方法
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US11273124B2 (en) * 2019-05-23 2022-03-15 Brown University Antifungal nanoparticles for targeted treatment of fungal infections
CN114177278A (zh) * 2021-10-18 2022-03-15 山东多美康生物医药有限公司 脂质体制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
KR100679906B1 (ko) * 1998-09-16 2007-02-07 알자 코포레이션 리포솜-엔트랩된 토포이소머라제 억제제
US8518437B2 (en) * 2001-11-13 2013-08-27 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
CN107811971B (zh) * 2004-05-03 2021-10-29 益普生生物制药公司 用于药物输送的脂质体
ES2594621T3 (es) * 2004-06-01 2016-12-21 Kabushiki Kaisha Yakult Honsha Preparación de irinotecán
CN1326525C (zh) * 2004-11-26 2007-07-18 复旦大学 10－羟基喜树碱长循环脂质体及其冻干制剂
EP1976485A4 (en) * 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR THE PREPARATION OF SAID FORMULATIONS
US7489990B2 (en) * 2006-07-17 2009-02-10 Fehr Stephen L Systems and methods for calculating and predicting near term production cost, incremental heat rate, capacity and emissions of electric generation power plants based on current operating and, optionally, atmospheric conditions
CN101019834A (zh) * 2006-12-31 2007-08-22 西安力邦医药科技有限责任公司 注射用7－乙基－10羟基喜树碱脂质体的制备方法
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
AU2008227852B2 (en) 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物

Also Published As

Publication number Publication date
KR20160140992A (ko) 2016-12-07
US10022365B2 (en) 2018-07-17
RU2012123875A (ru) 2014-01-20
KR101780915B1 (ko) 2017-09-21
PL2508170T3 (pl) 2015-12-31
CA2782911A1 (en) 2011-06-09
EP2508170A1 (en) 2012-10-10
AU2009356132A1 (en) 2012-06-21
JP5645954B2 (ja) 2014-12-24
EP2508170B1 (en) 2015-07-29
RU2526114C2 (ru) 2014-08-20
HK1159482A1 (en) 2012-08-03
SI2508170T1 (sl) 2015-12-31
US20120282325A1 (en) 2012-11-08
HRP20150911T1 (hr) 2015-10-23
ES2547698T3 (es) 2015-10-08
CY1116811T1 (el) 2017-03-15
CN102271659A (zh) 2011-12-07
CA2782911C (en) 2016-08-23
BR112012012151B1 (pt) 2021-01-19
US20170189392A1 (en) 2017-07-06
CN102271659B (zh) 2013-09-18
AU2009356132B2 (en) 2015-01-22
BR112012012151A2 (pt) 2016-04-12
MX2012005775A (es) 2012-06-13
DK2508170T3 (en) 2015-09-21
WO2011066684A1 (zh) 2011-06-09
HUE027467T2 (en) 2016-10-28
SMT201500245B (it) 2015-10-30
JP2013512262A (ja) 2013-04-11
EP2508170A4 (en) 2014-01-15
PT2508170E (pt) 2015-10-16
KR20120089754A (ko) 2012-08-13
ZA201203316B (en) 2013-11-27

Similar Documents

Publication Publication Date Title
BR112012012151B8 (pt) lipossoma de irinotecano ou cloridrato de irinotecano, método de preparação do mesmo, bem como injeção de lipossoma e processo de preparação da mesma
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
BR112018076600A2 (pt) processo para a preparação de derivado de piridona policíclica substituída e cristal do mesmo
BR112014013964A2 (pt) método para fazer uma componente de lignina, um componente de lignina e seus usos e um produto
CU20130137A7 (es) Derivados de ácido 3- fenilpropiónico ramificados y su uso
BR112013033420A2 (pt) microemulsão de polissiloxanas contendo grupos amônio quaternário, sua preparação e uso
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
NI201400036A (es) Compuestos con actividad nematicida
EA201190242A1 (ru) Липидные композиции
PA8841901A1 (es) Compuestos orgánicos
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112013031021A2 (pt) composições e métodos para a inibição da expressão de gene do vírus da hepatite b'
UY32799A (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
BR112014015066A2 (pt) derivados de nucleosídeos 4'azido-3'-flúor substituídos como inibidores de replicação do rna de hcv
AR079152A1 (es) Inhibidores de glucosilceramida sintasa
BR112014010713A2 (pt) compostos com atividade nematicida
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BR112013017845A2 (pt) agente antidiabético de abaixamento de lipídio
BR112014017762A8 (pt) Derivados de furo[3,2-b]- e tieno[3,2-b]piridina como inibidores de tbk1 e ikk, seus usos, processo para a preparação dos mesmos e medicamentos que os compreendem
BR112014005018A8 (pt) composição aquosa de ligante, ligante, método de produção de uma composição aquosa de ligante e método de fabricação de um produto selecionado de um grupo
BR112014013483A2 (pt) análogo de insulina humana e derivado acilado do mesmo
BR112013003682A2 (pt) métodos para tratar doenças neurodegenerativas
BR112012012903A2 (pt) compostos de espiropiperidina
BR112015007295A2 (pt) processo para a preparação de compostos; compostos; e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2751 DE 26-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.